Synthetic oligosaccharides composed of several repeats of Shigella dysenteriae type 1 O-specific polysaccharide (O-SP), bound by their reducing ends to a carrier protein ("sun" type configuration), induced in mice significantly higher antibody levels than conjugates of the native O-SP ("lattice" type configuration). Here we present isolation and characterization of low molecular mass oligosaccharides of Shigella sonnei lipopolysaccharides and their conjugation to several carrier proteins. Conjugates were formed by oxime linkages between the terminal Kdo residues of the reducing ends of the saccharides and aminooxy linkers bound to the protein. IgG antibody levels induced in young outbread mice by these conjugates were significantly higher than those prepared with the full length native O-SP. We propose clinical evaluation of the new S. sonnei conjugates.
Shigellae cause endemic and epidemic diarrhea and/or dysentery worldwide, especially in developing countries. At least one half the cases and deaths occur in children less than 5 years old. Despite its discovery over a century ago, there is still no licensed vaccine for shigellae. Residual morbidity, even after effective antibiotic therapy, and increasing antibiotic resistance of shigellae urge the development of vaccines to prevent disease caused by this pathogen.
Lipopolysaccharides (LPS) of Shigella are essential virulence factors. An LPS-based vaccine elicited 74 % protection against shigellosis in Israeli Army recruits at 8-14% infection rates [1] . The efficacy was related to vaccine induced IgG anti-O-SP levels. Evaluation of such conjugates in children, having highest incidence and severity of S. sonnei shigellosis, showed an age related antibody responses and protection.
A significant improvement in the immunogenicity of S. dysenteriae type 1 conjugates was achieved using short synthetic fragments of O-SP bound by their reducing ends to a protein carrier [2] .
However the synthesis of S. sonnei O-SP oligosaccharides has not been possible to date. We used therefore low mass O-SP-core (O-SPC) fragments isolated from the LPS to bind to carrier proteins, similarly to the preparation of the synthetic S. dysenteriae type 1 oligosaccharide-protein conjugates.
LPS from S. sonnei strain 53G was extracted by the hot phenol method and purified by ultracentrifugation. Next, LPS was hydrolyzed with 1% acetic acid at 100°C for 1.5 h, Lipid A removed by ultracentrifugation and the soluble product subjected to gel chromatography on a BioGel P-10 (1x100 cm) column in pyridine/acetic acid/water buffer (4/8/988 ml). Four fractions were obtained and analyzed by NMR and mass spectroscopy [1] . Integration of the O-SP FucNAc4N methyl signal in 1 H-NMR spectra products. Fraction F2 (O-SPC-F2) was analyzed in detail and the following structure was assigned: Mice (10 per group) were injected with 2.5 μg of saccharide as a conjugate per mouse, 3 times, 2 weeks apart and bled one week after the last two injections.
Conclusion
Protein conjugates of the low molecular mass oligosaccharides containing LPS core plus average 2-5 O-SP repeat units (O-SPC) were prepared and characterized by physico-chemical and immunogenicity assays. These conjugates induced significantly higher IgG antibody levels then those method is being studied with S. flexneri 2a, 6 and S. dysenteriae type 1 LPS. The mild reaction conditions and relative ease of preparation provided by O-SPC may be applicable for the preparation of conjugates against other Gram-negative pathogens such as non-typhoidal Salmonella or Escherichia coli O157.
